Evidence map›Paper›PMID 32817085›Full record

ArticleJournal of clinical microbiology2020

Laboratory Evaluation of a Lateral-Flow Cell for Molecular Detection of First-Line and Second-Line Antituberculosis Drug Resistance.

Donald G Catanzaro, Rebecca E Colman, Yvonne Linger, Sophia B Georghiou, Alexander V Kukhtin, Marva Seifert, Rebecca C Holmberg, Haifa Mshaiel, Peter Chiles, Naomi Hillery and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Detecting rifampin and isoniazid resistance inJournal of clinical tuberculosis and other mycobacterial diseases · 2022
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Donald G Catanzaro *Department of Biological Sciences, University of Arkansas, Fayetteville, Arkansas, USA dgcatanz@uark.edu.ORCID 0000-0003-1760-0574
Rebecca E Colman *Department of Medicine, University of California, San Diego, La Jolla, California, USA.ORCID 0000-0002-6854-2100
Yvonne LingerAkonni Biosystems, Inc., Frederick, Maryland, USA.
Sophia B GeorghiouFIND, Geneva, Switzerland.
Alexander V KukhtinAkonni Biosystems, Inc., Frederick, Maryland, USA.
Marva SeifertDepartment of Medicine, University of California, San Diego, La Jolla, California, USA.ORCID 0000-0002-7554-6396
Rebecca C HolmbergAkonni Biosystems, Inc., Frederick, Maryland, USA.
Haifa MshaielDepartment of Medicine, University of California, San Diego, La Jolla, California, USA.
Peter ChilesDepartment of Medicine, University of California, San Diego, La Jolla, California, USA.
Naomi HilleryDepartment of Family Medicine and Public Health, University of California, San Diego, La Jolla, California, USA.
Christopher G CooneyAkonni Biosystems, Inc., Frederick, Maryland, USA.
Timothy C RodwellDepartment of Medicine, University of California, San Diego, La Jolla, California, USA.
University of California San Diego · USAkonni Biosystems (United States) · USFIND · CHUniversity of Arkansas at Fayetteville · US

Funding

UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI David Mitchell Smith · 1994 to 2026
$78.4M
An Integrated Tabletop Platform for Rapid Detection of XDR-TB in Clinical SamplesR01AI111435 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RODWELL, TIMOTHY CHARLES · 2014 to 2018
$5.4M
TB Diagnostics at the Point of CareR44AI138903 · NIAID · AKONNI BIOSYSTEMS, INC. · PI COONEY, CHRISTOPHER GERARD · 2018 to 2020
$3.0M
NCATS NIH HHS UL1 TR001442NIAID NIH HHS P30 AI036214NIAID NIH HHS R01 AI111435NIAID NIH HHS R44 AI138903
6 · The paper itself

Abstract

Despite the WHO's call for universal drug susceptibility testing for all patients being evaluated for tuberculosis (TB), a lack of rapid diagnostic tests which can fully describe TB resistance patterns is a major challenge in ensuring that all persons diagnosed with drug-resistant TB are started on an appropriate treatment regime. We evaluated the accuracy of the Akonni Biosystems XDR-TB TruArray and lateral-flow cell (XDR-LFC), a novel multiplex assay to simultaneously detect mutations across seven genes that confer resistance to both first- and second-line anti-TB drugs. The XDR-LFC includes 271 discrete three-dimensional gel elements with target-specific probes for identifying mutations in

Indexed as

Mycobacterium tuberculosisTuberculosis, Multidrug-ResistantAntitubercular AgentsBacterial ProteinsDrug Resistance, Multiple, BacterialHumansLaboratoriesMicrobial Sensitivity TestsMutationAntitubercular AgentsBacterial Proteinsamikacincapreomycindrug susceptibilityextensively drug-resistant tuberculosisfluoroquinoloneisoniazidkanamycinlateral-flow cellrifampintuberculosis

Identifiers

PMID32817085
PMCPMC7587100
OpenAlexW3069962137

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.